ASX Health Stocks: More positive data for Recce’s drug, Cynata expects trial results in Q1

Recce Pharma announces further positive data on RECCE 327
Cynata says results from Phase 1 will be released in Q1 2024

Recce Pharma shares further positive data

Synthetic anti-infectives biotech, Recce Pharma (ASX:RCE), has just announced further positive efficacy data on its lead drug, RECCE 327 (R327).

The latest data released by the Murdoch Children’s Research Institute in a rat model shows that R327 has significant antibacterial activity against Escherichia coli (E. coli) urinary tract infections (UTI).

The study in rats resulted in over a >99% reduction of E. coli UTI, when using 500 mg/kg dosing of R327 via a 1-hour intravenous infusion.

A reduction of bacterial load in urine at 6-hours post-infection (6phi) was also observed.

UTIs are most commonly caused by E. coli bacteria (Gr-) with over 400 million people worldwide contracting UTI in 2019. If undiagnosed or untreated, UTIs can progress to systemic bacteraemia infections, which can trigger sepsis and septic shock.

Meanwhile, R327 is Recce’s potential drug that’s currently undergoing a Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial.

The company says the results from the Murdoch Children’s Research Institute will support the ongoing trial.

“This instils confidence in the prospect of advancing R327 to a Phase II clinical trial for UTI/Urosepsis,” said James Graham, CEO of Recce Pharma.

Cynata expects trial results in Q1 2024

Cell therapeutics company, Cynata Therapeutics (ASX:CYP), says it anticipates receiving initial results from the Phase 1 clinical trial of CYP-006TK in diabetic foot ulcer (DFU )in Q1 2024.

The company has initiated analysis of wound surface area in the first 16 patients, which be followed up in 10 weeks.

At each visit in this trial, 3-dimensional images of the study ulcer are taken using specialised camera equipment.

Images are then analysed by a technician who is independent of the clinical site and blind to treatment allocation. This facilitates calculation of the wound surface area, and consequently the change in the size of the wound over time.

Encouraging initial results from the first six patients enrolled in this trial up to Day 28 have previously been released, which showed an increased level of wound healing.

Meanwhile, CYP-006TK is Cynata’s Cymerus off-the-shelf MSC (mesenchymal stem cell) topical wound dressing product, which comprises MSCs seeded onto a novel silicon dressing.

“We have partnered with a specialist imaging contract research organisation, and we are working with them to deliver this analysis as soon as possible. We look forward to releasing these initial results in the near future,” said Cynata CEO, Dr Kilian Kelly.